Potential conflict of interest
Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.1080/10428194.2016.1201573.
Funding
This study has been completed by the following Cooperative Group Networks: SWOG, CALGB/Alliance, ECOG, and the AIDS Malignancy Consortium.
This investigation was supported in part by the following PHS/DHHS grant numbers awarded by the National Institutes of Health (NIH) National Cancer Institute (NCI), National Clinical Trials Network (NCTN): CA180888, CA180819, CA180821, CA180820, CA180799, CA180816, CA180801; CA180835; CA180858, CA180801, CA180846, CA180835, CA180818, CA180828, CA180826, CA180834; by the NIH/NCI Community Oncology Research Program (NCORP): CA189830, CA189971, CA189808, CA189854, CA189821, CA189848, CA189858, CA189860, CA189872, CA189856; by NIH/NCI legacy grants CA31946, CA 46368, CA35119, CA13612, CA46282, CA68183, CA37981, CA12644, CA76448, CA46136, CA58416; by the NCI AIDS Malignancy Clinical Trials Consortium (AMC): CA121947 and by the NIH American Recovery and Reinvestment Act of 2009 (ARRA) grant 3U10CA032102-30S1. AVD is supported by the Lymphoma Research Foundation Clinical Investigator Career Development Award.